动物造模,肺缺血再灌注损伤 Z-bio 2023-03-21 267

　　Objective To investigate the effect of dexmedetomidine combined with sufentanil on pulmonary ischemia-reperfusion injury (LIRI) in rats.

　　Methods SD rats were randomly divided into sham operation group, model group, sufentanil treatment group, dexmedetomidine treatment group, and sufentanil+dexmedetomidine treatment group. In addition to the sham operation group, the remaining 4 groups of rats were given 20 μ G/kg sufentanil, 25 two μ G/kg dexmedetomidine and 20 μ G/kg sufentanil+25 two μ G/kg dexmedetomidine, and then establish a LIRI model. After the experiment, the structure of lung tissue was observed by HE staining and TUNEL staining, the mitochondrial damage of lung cells was observed by electron microscopy, the levels of SOD and MDA in lung tissue were detected by ELISA, and the levels of LC3B, Beclin1, ATG5, HO-1, and Nrf-2 proteins in lung tissue were detected by Western blot.

　　Result 20 μ G/kg sufentanil and 25 two μ "G/kg dexmedetomidine and its combined use improved lung tissue injury in LIRI rats, reduced lung cell apoptosis, reduced mitochondrial swelling of lung cells, and decreased the expression of SOD and MDA. In addition, it also decreased the expression of LC3B - Ⅱ, Beclin1, ATG5 proteins, and the ratio of LC3B - Ⅱ to LC3B - Ⅰ, and increased the expression of LC3B - Ⅰ, Nrf-2, and HO-1 proteins, among which 20" μ G/kg sufentanil composite 25 two μ G/kg dexmedetomidine performed best among the three treatment groups.

　　Conclusion Both dexmedetomidine, sufentanil, and their combination are effective in protecting LIRI in rats. The synergistic effects of dexmedetomidine and sufentanil on improving LIRI in rats may be related to activating the Nrf-2/HO-1 antioxidant stress pathway and inhibiting excessive autophagy.